STOCK TITAN

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Chimerix to host conference call and webcast to report Q3 2023 financial results and provide business overview
Positive
  • Chimerix will host a live conference call and webcast on November 2, 2023, to report its financial results for Q3 2023. Investors can access the call and webcast through the company's website. This provides an opportunity for investors to gain insights into Chimerix's performance and future plans.
Negative
  • None.

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview.

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5615320. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com


FAQ

When will Chimerix report its Q3 2023 financial results?

Chimerix will report its Q3 2023 financial results on November 2, 2023.

How can investors access the conference call and webcast?

Investors can access the conference call and webcast through the Investors' section of Chimerix's website.

What is the purpose of the conference call and webcast?

The conference call and webcast will provide a business overview and insights into Chimerix's performance and future plans.

Chimerix, Inc.

NASDAQ:CMRX

CMRX Rankings

CMRX Latest News

CMRX Stock Data

82.46M
74.39M
1.34%
50.01%
1.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DURHAM

About CMRX

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed